1. Home
  2. SST vs TXMD Comparison

SST vs TXMD Comparison

Compare SST & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

N/A

Current Price

$2.72

Market Cap

27.4M

ML Signal

N/A

Logo TherapeuticsMD Inc.

TXMD

TherapeuticsMD Inc.

N/A

Current Price

$2.32

Market Cap

25.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SST
TXMD
Founded
2013
2008
Country
United States
United States
Employees
300
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
25.9M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
SST
TXMD
Price
$2.72
$2.32
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
8.2K
23.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
80.61
EPS
N/A
N/A
Revenue
N/A
$1,761,000.00
Revenue This Year
N/A
$427.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$90.64
Revenue Growth
N/A
35.25
52 Week Low
$0.29
$0.72
52 Week High
$11.30
$2.95

Technical Indicators

Market Signals
Indicator
SST
TXMD
Relative Strength Index (RSI) 29.29 50.84
Support Level $0.34 $2.07
Resistance Level $4.71 $2.54
Average True Range (ATR) 0.24 0.11
MACD -0.02 -0.01
Stochastic Oscillator 11.70 68.93

Price Performance

Historical Comparison
SST
TXMD

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Share on Social Networks: